21st October 2009

ASX RELEASE

IMPEDIMED APPOINTS VICE PRESIDENT QUALITY AND REGULATORY

ImpediMed CEO Greg Brown today announced the appointment of Mr Alden Kay as the VP of Quality and Regulatory. Mr Kay will be located at the Company’s San Diego facility in the United States. Mr Brown said the appointment reaffirmed ImpediMed’s strategic choice to establish the San Diego facility as the global operations hub, to support a focus on the group’s key growth market in the US.

Mr Kay has a wealth of operational, regulatory and quality management experience at a senior executive level, with a strong focus on the medical device sector in the United States.

Mr Brown said the appointment of Alden was a significant step forward in positioning ImpediMed as a stand out medical device manufacturer with the operational systems to comply with FDA, TGA and international regulatory standards. Mr Kay is experienced to the very highest 6 Sigma level, usually only seen in multinational companies, Mr Brown added.

Mr Alden said he was excited to be joining the ImpediMed team and the opportunity to be part of the journey in positioning the company as a leader in the specialized medical device field focussing on cancer patient management. “I believe we can make a real difference to the quality of life of patients post surgery and radiation,” he added.

Mr Brown said the appointment of a VP of Quality and Regulatory was part of an ongoing commitment to build a highly experienced senior executive team to manage the roll out of the company’s global launch.

Further announcements will follow as new appointments are made.

ENDS

For further information contact:

Greg Brown  ImpediMed CEO  +61 408281127

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit www.impedimed.com.